Viral Shah, MD, an endocrinologist and scientist, discusses the growing field of research into the connections between type 1 diabetes (T1D) and osteoporosis.
There are gender differences in bone fracture risk, osteoposoris, and type 1 diabetes that are still being explored, according to Viral Shah, MD, an endocrinologist and associate professor of medicine and pediatrics at the Barbara Davis Center for Diabetes, Adult Clinic School of Medicine at the University of Colorado Anschutz campus.
Transcript
What is the relationship between type 1 diabetes and osteoporosis and bone fractures?
That's a great question. I have been involved in research of type 1 diabetes and osteoporosis for now, a couple of years, and it's very interesting. Little is known about how type 1 diabetes influences the bone. First, we looked around the literature and tried to see what's the fracture risk in people with type 1 diabetes, and it's very surprising.
We found out that, particularly females, postmenopausal females with type 1 diabetes have a 6-fold higher risk for fractures than females without diabetes. And not only that, men with type 1 diabetes also have a higher fracture risk than females without diabetes. So with that research, it was a very surprising finding that the fracture risk was very high in people with type 1 diabetes. And that made us do more research about why people with type 1 diabetes are having a higher fracture risk.
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
New AI Tool Identifies Undiagnosed PNH in Health Records
October 30th 2024The machine learning model shows promise in detecting paroxysmal nocturnal hemoglobinuria (PNH) by assessing electronic health records (EHR) data, potentially transforming the diagnostic landscape for rare diseases.
Read More
Zanubrutinib More Effective Than Ibrutinib in Treating Patients With Relapsed/Refractory CLL, SLL
October 30th 2024The long-term response rate for zanubrutinib was better than ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
New AI Tool Identifies Undiagnosed PNH in Health Records
October 30th 2024The machine learning model shows promise in detecting paroxysmal nocturnal hemoglobinuria (PNH) by assessing electronic health records (EHR) data, potentially transforming the diagnostic landscape for rare diseases.
Read More
Zanubrutinib More Effective Than Ibrutinib in Treating Patients With Relapsed/Refractory CLL, SLL
October 30th 2024The long-term response rate for zanubrutinib was better than ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Read More
2 Commerce Drive
Cranbury, NJ 08512